A combination therapy targeting the proteins mediating these epigenetic aberrations, such as G9a/GLP or SUV39h1/h2, may be worth exploring for its potential to reduce resistance to chemotherapy and cancer relapse risk. Here, SUV39H1 is linked to cancer.